Lupin Ranks No.1 in S&P Global Sustainability Assessment

Lupin Limited has secured a place among the top 1% of companies worldwide in the S&P Global Corporate Sustainability Assessment (CSA), marking a major milestone in its sustainability journey.

With a score of 91 out of 100, Lupin emerged as the leading pharmaceutical company globally and the top-ranked company across all sectors in India, outperforming both domestic and international peers in the latest S&P Global Corporate Sustainability Assessment.

The S&P Global Corporate Sustainability Assessment is considered one of the most detailed ESG benchmarks in the world. It reviews companies on industry-specific economic, environmental, and social standards. Lupin has also been named in the Sustainability Yearbook 2026 for the third straight year.

Also Read: How a Culture of Thanks Fuels Retention in Hospitals

Selection is based on performance in the S&P Global 2025 Corporate Sustainability Assessment, where companies must rank in the top 15% of their industry and within 30% of the industry leader. Out of more than 9,200 companies assessed across 59 industries, only 848 made it to the Yearbook.

“This recognition by S&P Global places Lupin among the topmost global sustainability leaders and reinforces our long-term commitment to embedding ESG principles into our business strategy,” said Ramesh Swaminathan, executive director, global CFO and head of IT and API Plus SBU, Lupin. “It strengthens our resolve to accelerate our sustainability roadmap and deepen ESG integration across our value chain, while continuing to create positive outcomes for patients, communities, and stakeholders worldwide.”

The recognition highlights Lupin’s consistent focus on strong governance, environmental responsibility, and meaningful social impact across its global operations.